PubMed · 10981628
Engineering therapeutic proteins.
Abstract
Many early drug candidates derived from biotechnology failed in clinical trials because of their low affinity/specificity, short half-lives or immunogenicity. Protein engineering techniques have been applied to circumvent some of the problems that hindered these earlier trials, resulting in clinical benefits from a range of engineered antibodies and other proteins.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
J McCafferty, D R Glover. 2000. Engineering therapeutic proteins.. https://doi.org/10.1016/s0959-440x(00)00108-1
Cite the original work for its findings. Save a collection to share your selection of sources.